HD-OPM Archive
Topics › Aspirin, antiplatelets & blood thinners

ASPREE: aspirin tied to 70% lower dementia with high platelet-count genetic scores

Louis Nervegna · Oct 02, 2026 · ♥ 10 reactions · 4 comments · original Facebook post
Aspirin, antiplatelets & blood thinnersBrain health & dementia
AI summary & key facts

Monash researchers analysed genetic data from 13,541 ASPREE participants and found that among those in the top 20% of a platelet-count polygenic score, 1% on 100 mg aspirin developed dementia versus 3.3% on placebo. Aspirin is not recommended for dementia prevention, and this is a genetic subgroup finding that needs confirmation, with bleeding risk to weigh.

Daily low-dose aspirin might protect a subset of older adults against dementia.

These results are from the ASPREE randomized trial.

Low-dose daily aspirin is linked to a 70% lower relative risk of dementia in older adults who carry a specific genetic profile tied to platelet count.

Link to journal paper:

Paper · Alzheimer's & Dementia · 2026Platelet count polygenic scores may modify the effect of aspirin in primary prevention of dementiaINTRODUCTION Aspirin is not recommended for dementia prevention due to limited benefit. We investigated whether genetic subgroups may benefit. METHODS In the ASPirin in Reducing Events in the Elderly (ASPREE) trial ( n = 13,541), we screened 5182 polygenic risk scores (PGSs) for aspirin interactions on dementia and major bleeding. After quality control, 1848 PGSs were analyzed using Cox models for aspirin×PGS…alz-journals.onlinelibrary.wiley.com

Study Overview

Key Findings

Important Caveats and Risks

#aspirinHD #dementiaHD #aspreeHD

Research cited

A daily low dose of aspirin may offer protection against dementia for a specific group of older adults, according to a new analysis of one of the largest aspirin trials ever conducted. The findings suggest genetics could determine who receives cognitive benefits from the drug.

Researchers examined genetic data from more than 13,500 participants in the ASPREE trial, which originally tested daily 100-milligram aspirin against a placebo in healthy older adults. The new analysis focused on genetic variants associated with platelet count.

Among participants in the highest 20 percent for a platelet-related genetic score, about 1 percent of aspirin users developed dementia, compared with 3.3 percent receiving placebo, representing roughly a 70 percent lower risk.

However, this finding does not mean older adults should start taking aspirin to prevent dementia. The original ASPREE trial, involving more than 19,000 people, found no significant overall reduction in dementia, Alzheimer’s disease, mild cognitive impairment or cognitive decline among people taking aspirin.

Aspirin also increases bleeding risk. In ASPREE, major hemorrhage occurred more frequently among aspirin users than among participants receiving placebo. The new results therefore point toward personalized prevention rather than universal aspirin use.

Researchers need additional studies to confirm whether genetic testing can reliably identify people whose potential neurological benefits outweigh aspirin’s risks.

Until then, older adults should not begin daily aspirin specifically for dementia prevention without discussing their individual cardiovascular and bleeding risks with a healthcare professional.

Source: Monash University, ASPREE study; Alzheimer’s & Dementia, 2026.

May be an image of text
← newer: CoQ10 rejuvenated aging platelet-producing cells in mice viaolder: Two slices of deli meat a day linked to 44% higher dementia →